Neuraminidase inhibitor exposure during pregnancy not linked to adverse neonatal outcomes
Infants born to 5,824 women who received a prescription for a neuraminidase inhibitor during pregnancy had no increased risk of adverse neonatal outcomes or congenital malformations.
Neuraminidase inhibitors are recommended for women exposed to the influenza virus during pregnancy, but there are limited data available about their effect on infant outcomes.
To investigate, a team of researchers analysed registry data from Denmark, Norway, Sweden and France involving 698,056 women and their infants who were born between 1 January 2008 and 31 December 2010.
The researchers found that infants born to the 5,824 (0.8%) women who received a prescription for a neuraminidase inhibitor during pregnancy had no increased risk of adverse neonatal outcomes or congenital malformations compared with the other infants in the study.
Reporting in The BMJ (online, 28 February 2017), the researchers say that the findings from this large multinational study support those from previous research.
Citation: Clinical Pharmacist DOI: 10.1211/CP.2017.20202513
Recommended from Pharmaceutical Press
An innovative book which presents statistics in the context of clinical trials conducted during pharmaceutical drug development.£38.00Buy now